Vesicular Nanocarriers in Transdermal Drug Delivery| Chapter 2 | Pharmaceutical Research: Recent Advances and Trends Vol. 7

Nanocarriers are advanced materials at the nanoscale, designed to enhance drug delivery. Their ability to transport both hydrophobic and hydrophilic drugs is vital, as hydrophobic drugs often struggle with solubility and bioavailability. Nanocarriers improve these aspects by protecting drugs from degradation and facilitating their transport through the bloodstream. Despite their benefits, challenges such as potential toxicity, especially from inorganic nanomaterials, require careful consideration. Advances in protein-based nanocarriers, which are biocompatible and biodegradable, show promise in overcoming these challenges. In transdermal drug delivery, nanocarriers like liposomes, niosomes, ethosomes, and others, enhance drug penetration through the skin's barriers, improving therapeutic efficacy. However, issues like skin barrier penetration, cytotoxicity, and carrier stability remain areas for ongoing research. As this field evolves, nanocarriers hold significant potential to revolutionize drug delivery by offering targeted, sustained release with minimized systemic toxicity.

 

Author (s) Details

T. Praveen Kumar
Department of Pharmaceutics, Anurag Pharmacy College (Affiliated to JNTUH, Hyderabad), Kodad, Telangana, India.

 

Please see the book here:- https://doi.org/10.9734/bpi/prrat/v7/2489

Microbiologist's Perspective on Innovative Triple-Action Antifungal Topicals: A New Frontier | Chapter 3 | Research Perspectives of Microbiology and Biotechnology Vol. 1

This study investigated the effectiveness of triple-action antifungals containing azoles, gentamicin, and corticosteroids for superficial mycoses treatment. The antifungal association on the one hand with antibacterials will reduce the composition of the colonizing microbiota and promote fungal growth and improve fungal pathogenicity indirectly. The study identified 34 different antifungals in 588 pharmacies, with 47.05% being triple-action. While these combinations were expected to have excellent antifungal activity and prevent resistance, concerns arise regarding their impact on microbiota and potential for promoting fungal growth and pathogenicity. We suggest prioritizing antifungals without antibiotic and anti-inflammatory combinations to reduce recurrence rates.

Author(s) Details:

I. E. Kasamba,
Department of Biomedical Sciences, Faculty of Medicine, University of Lubumbashi, Democratic Republic of the Congo.

Please see the link here: https://stm.bookpi.org/RPMAB-V1/article/view/13761

 Because of the impermeable structure of human nails, onychomycosis is a common and difficult to cure fungus infection of the nails. Because topically applied antifungals are unable to permeate this structure, treatment regimens frequently turn to systemic antifungals, which come with their own set of side effects. According to a recent clinical trial, mechanical fenestration of the nail with an intelligent nail drill could be a viable solution to this issue. An in vitro model of antifungal drug transungual administration is given in this paper.  Real nail tissue and an inline flow system are used in this system. After 42 days, this technique was used to measure transungual distribution of ciclopirox, and it was discovered that nail fenestration enhanced drug delivery by 3–4 times. This research backs up the idea that nail fenestration should be accepted as a pretreatment for onychomycosis, and it also provides an opportunity to test new medications or formulations to attack the disease. Prior to clinical trials, the in vitro model reported here would be an excellent approach for directly measuring transungual distribution of antifungal drugs.

Author (s) Details

Damian Cordoba Díaz
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain.

Marta Elena Losa Iglesias
Facultad Ciencias de la Salud, Universidad Rey Juan Carlos, 28933 Madrid, Spain.

Ricardo Becerro de Bengoa Vallejo
Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, 28040 Madrid, Spain.

Manuel Cordoba Diaz
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain.


View Book  : - https://stm.bookpi.org/TIPR-V3/article/view/1144